FindTrial
Sign In

SOLUPRED 5 mg

DRUG4 trials

Sponsors

Insel Gruppe AG, Centre Hospitalier Universitaire De Nantes, Centre Hospitalier Universitaire Amiens Picardie, Assistance Publique Hopitaux De Paris

Conditions

Adult patients with a diagnosis of fibrotic Hypersensitivity Pneumonitis (HP) (“definite” or “high confidence”) after multi-disciplinary discussion (MDD) with a mild to moderate disease severityFocal cerebral arteriopathy and childhood stroke Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection.and never treated for fibrotic HP.kidney transplantationsuperficial arteriovenous malformations

Phase 2

MAV-RAPA: Prospective evaluation of the efficacy of sirolimus (Rapamune) in the treatment of superficial arteriovenous malformations.
Not yet recruitingCTIS2024-516001-23-00
Centre Hospitalier Universitaire Amiens Picardiesuperficial arteriovenous malformations
Target: 50Updated: 2025-01-17

Phase 3

Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant recipients selected according to the AGORA algorithm for their low immunological risk and medium-term graft failure
RecruitingCTIS2022-502624-44-00
Centre Hospitalier Universitaire De Nanteskidney transplantation
Start: 2024-12-10Target: 343Updated: 2024-10-21
High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial
Not yet recruitingCTIS2022-500631-36-00
Insel Gruppe AGFocal cerebral arteriopathy and childhood stroke Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection.
Target: 45Updated: 2025-11-14
RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»
Not yet recruitingCTIS2025-521591-64-00
Assistance Publique Hopitaux De ParisAdult patients with a diagnosis of fibrotic Hypersensitivity Pneumonitis (HP) (“definite” or “high confidence”) after multi-disciplinary discussion (MDD) with a mild to moderate disease severity, and never treated for fibrotic HP.
Target: 120Updated: 2026-08-03